april data continu trend show stabil price continu
annual difficult comp recent earn call teva
manag state activ discuss custom optim
portfolio estim abl rais price approxim
product discuss payer teva aim phase
product profit look top drug product group
consolid ndc molecul strength dosag form price declin
y/i versu last month y/i m/m price across ndc
ndc saw deflat y/i inflat m/m
month data along weve seen sinc januari give us confid
gener price trough cycl dont expect return
inflationari trend seen mid-singl digit deflat seem
equilibrium price inject appear remain strong compar
y/i deflat immediate-releas solid oral product seen far
note increas inject broad base
inject ndc price increas compar march
februari inject ndc look deeper much increas driven
inject ndc price increas month
commentari drug wholesal also echo sentiment manufactur
gener price stabil though perhap quit degre
manufactur manag state see gener price
stabl continu track high-singl digit
line expect cardin health manag similarli state
believ price deflat slightli wors mid-singl digit better y/i
q/q point continu price pressur gener
intim outsid expect
launch coverag ipxl pt rate ow month ad key
product new ipxl/amn includ gener epipen aggrenox
concerta ipxl launch product total
third highest industri behind teva
ir solid oral product declin y/i m/m er solid oral product
declin y/i m/m inject continu show categori strength
increas y/i m/m inflat inject driven
select number product includ amikacin inj bupivacain inj
leucovorin inj topic dermatolog decreas y/i
m/m ophthalm product increas y/i m/m price
narcot went y/i m/m driven inject narcot
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
present variou gener price trend month base analysi
proprietari price data believ give accur represent
dynam industri versu wac addit macro level price trend also
present variou compani specif metric relat coverag addit
regularli includ perspect relat gener market place separ
analysi price data
base analysi predict acquisit avail glass
analyt back-test measur cost gener purchas distributor
analysi includ ndc order provid accur broader pictur
normal data correct irregular extraordinari price increas
disproportion skew data also aim provid pictur
base gener busi exclud ndc launch within last month
order mute effect larg price declin seen exclus end
new gener manufactur enter market also analyz data calcul
price chang one ndc per product exampl atorvastatin mg
associ ndc indic differ manufactur packag size
also look top drug group im sale look
import gener product categori industri
also look price trend across ndc arguabl bia data
product sku packag size dosag strength believ provid
insight market trend show improv well
significantli smaller magnitud top drug product group analysi
histogram distribut price chang ndc
incorpor analysi note chart vast major ndc
experienc price deflat product price increas last three
month number signific increas
averag seen novemb januari
distribut y/i price chang april
distribut y/i price chang april oct april
also look number m/m price increas saw similar trend note
april ndc analyz price movement
versu march februari
distribut m/m price chang april march februari
figur depict number m/m price increas price decreas
highlight april april data show april ndc
experienc price increas substanti increas seen april
sinc decemb seen number price increas price
decreas converg even saw signific bump number price increas
februari time ndc increas price versu
period last year
number m/m price increas decreas time
inject continu show signific strength y/i price increas greater
past five month look deeper data show broad base
select number product drive increas given manufactur complex
fact fewer manufactur product inject much
suscept disrupt suppli chain thu compani abl take
price opportun tabl show number ndc y/i
price chang specifi rang support intuit larg price increas
product drive number april ndc price increas
compar march februari note ndc price
decreas month versu march februari
inject number ndc y/i price chang within specifi rang
notabl price chang coverag
calcul weight price chang individu molecul specif compani
within coverag use im volum ndc calcul weight price chang
molecul manufactur volum within differ product distribut
share differ ndc explain price molecul vari
dougla tsao herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
